Cancer Advances is focused on developing therapeutics for gastrin/ gastrin receptor (CCKB) producing tumors. The company’s lead product, Polyclonal Antibody Stimulator (PAS), is an immunomodulator that blocks the function of gastrin. This inhibition slows tumor growth, the incidence of metastasis, and also changes the tumor microenvironment.
PAS, An Interview with Lynda Sutton
Advancing Cancer Therapy
Our goal is to improve the quality of life and to extend the survival of patients with gastrointestinal cancers. Currently, Cancer Advances is focused on developing therapeutics for gastrin/ gastrin receptor (CCKB) producing tumors and exploring synergy between treatment classes. Our most recent nonclinical research suggests that PAS can be used to increase the efficacy of PD-1 Checkpoint Inhibitors by turning a pancreatic cancer tumor from “cold” to “hot”.
© 2020 Cancer Advances, Inc. All rights reserved.